Fingolimod does not enhance cerebellar remyelination in the cuprizone model

Journal of Neuroimmunology

Volumn 285, Issue , 2015, Pages 180-186

  Alme, Maria Nordheim ^a   Nystad, Agnes E ^a,b   Bø, Lars ^a,b   Myhr, Kjell Morten ^a,b   Vedeler, Christian A ^a,b   Wergeland, Stig ^a,b   Torkildsen, Øivind ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cerebellum; Cuprizone; Demyelination; Fingolimod; FTY720; Remyelination

Indexed keywords

CUPRIZONE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CEREBELLUM; CONTROLLED STUDY; DEMYELINATING DISEASE; FEMALE; IN VIVO STUDY; MICROGLIA; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CEREBELLUM; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84943255061     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.06.006     Document Type: Article

References (32)

1. Blakemore W.F. Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone. J. Neurol. Sci. 1973, 20:63-72.
2. Blakemore W.F. Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone. J. Neurol. Sci. 1973, 20:73-83.
3. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 2007, 115:84-105.
4. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., Aradhye S., Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
5. Deshmukh V.A., Tardif V., Lyssiotis C.A., Green C.C., Kerman B., Kim H.J., Padmanabhan K., Swoboda J.G., Ahmad I., Kondo T., Gage F.H., Theofilopoulos A.N., Lawson B.R., Schultz P.G., Lairson L.L. A regenerative approach to the treatment of multiple sclerosis. Nature 2013, 502:327-332.
6. Groebe A., Clarner T., Baumgartner W., Dang J., Beyer C., Kipp M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 2009, 8:163-174.
7. Groves A., Kihara Y., Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 2013, 328:9-18.
8. Gudi V., Moharregh-Khiabani D., Skripuletz T., Koutsoudaki P.N., Kotsiari A., Skuljec J., Trebst C., Stangel M. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 2009, 1283:127-138.
9. Hibbits N., Yoshino J., Le T.Q., Armstrong R.C. Astrogliosis during acute and chronic cuprizone demyelination and implications for remyelination. ASN Neuro 2012, 4:393-408.
10. Hu Y., Lee X., Ji B., Guckian K., Apicco D., Pepinsky R.B., Miller R.H., Mi S. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol. Cell. Neurosci. 2011, 48:72-81.
11. Ingwersen J., Aktas O., Kuery P., Kieseier B., Boyko A., Hartung H.P. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin. Immunol. 2012, 142:15-24.
12. Jaillard C., Harrison S., StankoffB., Aigrot M.S., Calver A.R., Duddy G., Walsh F.S., Pangalos M.N., Arimura N., Kaibuchi K., Zalc B., Lubetzki C. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 2005, 25:1459-1469.
13. Kim H.J., Miron V.E., Dukala D., Proia R.L., Ludwin S.K., Traka M., Antel J.P., Soliven B. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J. 2011, 25:1509-1518.
14. Meno-Tetang G.M., Li H., Mis S., Pyszczynski N., Heining P., Lowe P., Jusko W.J. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. 2006, 34:1480-1487.
15. Miron V.E., Franklin R.J. Macrophages and CNS remyelination. J. Neurochem. 2014, 130:165-171.
16. Miron V.E., Hall J.A., Kennedy T.E., Soliven B., Antel J.P. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 2008, 173:1143-1152.
17. Miron V.E., Jung C.G., Kim H.J., Kennedy T.E., Soliven B., Antel J.P. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 2008, 63:61-71.
18. Miron V.E., Schubart A., Antel J.P. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274:13-17.
19. Miron V.E., Ludwin S.K., Darlington P.J., Jarjour A.A., Soliven B., Kennedy T.E., Antel J.P. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 2010, 176:2682-2694.
20. Nair A., Frederick T.J., Miller S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life Sci. 2008, 65:2702-2720.
21. Nystad A.E., Wergeland S., Aksnes L., Myhr K.M., Bo L., Torkildsen O. Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS 2014, 122:1178-1186.
22. Praet J., Guglielmetti C., Berneman Z., Van Der Linden A., Ponsaerts P. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci. Biobehav. Rev. 2014, 47:485-505.
23. Skripuletz T., Lindner M., Kotsiari A., Garde N., Fokuhl J., Linsmeier F., Trebst C., Stangel M. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol. 2008, 172:1053-1061.
24. Skripuletz T., Bussmann J.H., Gudi V., Koutsoudaki P.N., Pul R., Moharregh-Khiabani D., Lindner M., Stangel M. Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol. 2010, 20:301-312.
25. Skripuletz T., Gudi V., Hackstette D., Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 2011, 26:1585-1597.
26. Slowik A., Schmidt T., Beyer C., Amor S., Clarner T., Kipp M. The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination. Br. J. Pharmacol. 2015, 172:80-92.
27. Sobel K., Monnier L., Menyhart K., Bolinger M., Studer R., Nayler O., Gatfield J. FTY720-P activates sphingosine-1-phosphate receptor 2 and selectively couples to Galpha12/13/Rho/ROCK to induce myofibroblast contraction. Mol. Pharmacol. 2015, 87(6):916-927.
28. Tanaka T., Yoshida S. Mechanisms of remyelination: recent insight from experimental models. Biomol. Concepts 2014, 5:289-298.
29. Torkildsen O., Brunborg L.A., Myhr K.M., Bo L. The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 2008, 188:72-76.
30. Torkildsen O., Brunborg L.A., Milde A.M., Mork S.J., Myhr K.M., Bo L. A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clin. Nutr. 2009, 28:83-87.
31. Wergeland S., Torkildsen O., Myhr K.M., Aksnes L., Mork S.J., Bo L. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS One 2011, 6:e26262.
32. Wergeland S., Torkildsen O., Myhr K.M., Mork S.J., Bo L. The cuprizone model: regional heterogeneity of pathology. APMIS 2012, 120:648-657.